

In re application of:

Avi ASHKENAZI, et al.

Application Serial No. 10/633,008

Examiner: Unassigned

Art Unit: 1641

Attorney's Docket No. 39766-0100 P1

Customer No. 25213

For: USE OF A33 ANTIGENS AND JAM-IT

EXPRESS MAIL LABEL NO. <u>EL 977 676 755 US</u>

Date Mailed: FEBRUARY 20, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop Missing Parts

Filed: July 31, 2003

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

apply):	This st	tatemer	It qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that			
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR			
		(2)	It is being filed within 3 months of entry of a national stage			
	\boxtimes	(3)	It is being filed before the mail date of the first Office Action on the merits OR			
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.			
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:					
		a certif	ication as specified in §1.97(e) is provided below; or			
		a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.				
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:					
	A.	a certif	ication as specified in §1.97(e) is completed below; and			
	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and				
	C.	a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.				
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Attorney's Docket No. 39766-0100 P1)</u> .					
			Respectfully submitted,			
Dated:	Februa	ary 20, 2	By: <u>Serlie Mon</u> Leslie A. Mooi (Reg. No. 37,047)			
275 Mid Menlo I	ddlefield Park, C		HITE & McAULIFFE LLP 5-3506			

-2-

Facsimile: (650) 324-0638

Sheet 1 of Form PTO-1449 Attorney's Docket No. **Application Serial No.** 39766-0100 P1 10/633,008 INFORMATION DISCLOSURE STATEMEN Applicant(s) Avi ASHKENAZI, et al. Filing Date: **Group Art Unit:** (use several sheets if necessary) July 31, 2003 1641 U.S. PATENT DOCUMENTS **Examiner** Ref. Date Document No. **Subclass** Name Class **Filing Date Initials** No. (if appropriate) 1. 04/01/86 4,579,827 Sakamoto et al. 436 536 FOREIGN PATENT DOCUMENTS Document No. Ref. **Date** Name Examiner **Translation Subclass** Class Initials No. **YES** NO 2. 10/29/86 0 199 141 15/00 Europe **C07K** 0 616 812 A1 09/28/94 **Europe** 39/395 **A61K** 0 616 812 B1 09/28/94 **A61K** 39/395 Europe OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Ref. Title **Examiner Initials** No. Boyum, A. "A One Stage Procedure for Isolation of Granulocytes and Lymphocytes from Human Blood," Norweigan **5**. Defense Establishment, Div. Of Toxicology, pp. 51-76 Martin-Padura, I. et al, "Junctional Adhesion Molecule, aNovel Member of the Immunoglobulin Superfamily That 6. Distributes at Intercellular Junctions and Modulates Monocyte Transmigration," J. Cell Biol. 142 (1): 117-27 (1998) 7. Monks, A. et al., "Feasibility of High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cel Lines," Natl. Cancer Inst. 83: 757-766 (1991) Skehan, P. et al., "New Colorimetric Cytoxicity Assay for Anticancer-Drug Screening," J. Natl. Cancer Inst. 82: 1107-8. 1112 (1990) Spencer, S. et al., "The Orphan Receptor CRF2-4 Is an Essential Subunit of the Interleukin 10 Recepto," J. Exp. Med. 9. <u>187</u>: 571-578 (1998). Taylor, S. et al., "The Human Homologue of Bub3 Is Required for Kinetochore Localization of Bub1 and a Mad3/Bub1-10. Related Protein Kinase," J. Cell. Biol. <u>142</u> (1): 1-11 (1998) Welt, S. et al., "Quantative Analysis of Antibody Localization in Human Metastatic Colon Cancer: A Phase I Study of 11. Monoclonal Antibody A33," J. Clin. Oncol. 8: 1894-1906 (1990) 12. Welt, S. et al., "Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients with Advanced Colon Cancer," J. Clin. Oncol. 12: 1561-1571 (1994)

EXAMINER:	-	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2009086 v2